HIGHLIGHTS
- who: American Medical Association from the (UNIVERSITY) have published the paper: Atezolizumab Plus Bevacizumab as First-line Treatment for Patients With Metastatic Nonsquamous Non-Small Cell Lung Cancer With High Tumor Mutation Burden: A Nonrandomized Controlled Trial, in the Journal: (JOURNAL)
SUMMARY
@@
ACRONYMS
LAY DEFINITIONS
- Bevacizumab: An anti-VEGF humanized murine monoclonal antibody. It inhibits VEGF RECEPTORS and helps to prevent PATHOLOGIC ANGIOGENESIS
- Cancer: Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.